CNS Pharmaceuticals | EFFECT: Others
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025
CNS Pharmaceuticals | 10-Q: Quarterly report
CNS Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Mahery Amy
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Keyes Jeffry R.
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gumulka Jerzy
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Evans Carl Anthony
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Downs Christopher
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Cockroft Bettina M.
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Climaco John M
CNS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Charles Faith L.
CNS Pharmaceuticals | DEF 14A: Definitive information statements
CNS Pharmaceuticals | 10-K: Annual report
CNS Pharmaceuticals | 8-K: Current report
CNS Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
CNS Pharmaceuticals | 8-K: Current report
No Data